J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

CHICAGO — When Leyla Shune first heard about a leaked abstract last month describing a dramatic 74% reduction in the risk of disease progression or …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23

Max Gelman

Senior Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Senior Editor

News Reporter

Sign up to read this article for free.

J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23